These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The sympathetic nervous system and ischaemic heart disease. Remme WJ Eur Heart J; 1998 Jun; 19 Suppl F():F62-71. PubMed ID: 9651738 [TBL] [Abstract][Full Text] [Related]
5. Anti-ischemic potential of drugs related to the renin-angiotensin system. Ertl G; Hu K J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S11-20. PubMed ID: 11392474 [TBL] [Abstract][Full Text] [Related]
6. Effect of ACE inhibition on myocardial ischaemia. Ferrari R Eur Heart J; 1998 Sep; 19 Suppl J():J30-5. PubMed ID: 9796838 [TBL] [Abstract][Full Text] [Related]
7. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. Enseleit F; Hürlimann D; Lüscher TF J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475 [TBL] [Abstract][Full Text] [Related]
8. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story. Ferrari R; Fox K Drugs; 2009; 69(3):265-77. PubMed ID: 19275271 [TBL] [Abstract][Full Text] [Related]
9. Rationale for ACE inhibition as an anti-ischaemic therapy. Pepine CJ Eur Heart J; 1998 Jul; 19 Suppl G():G34-40. PubMed ID: 9717054 [TBL] [Abstract][Full Text] [Related]
10. ACE-inhibitors in coronary artery disease? Vogt M; Motz W; Strauer BE Basic Res Cardiol; 1993; 88 Suppl 1():43-64. PubMed ID: 8357335 [TBL] [Abstract][Full Text] [Related]
11. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Ruschitzka FT; Lüscher TF Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622 [TBL] [Abstract][Full Text] [Related]
12. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors]. Tschudi MR; Noll G; Lüscher TP Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890 [TBL] [Abstract][Full Text] [Related]
13. Endothelial function and bradykinin in humans. Hornig B; Drexler H Drugs; 1997; 54 Suppl 5():42-7. PubMed ID: 9429844 [TBL] [Abstract][Full Text] [Related]
14. The role of calcium antagonists in ischaemic heart disease. Pepine CJ Eur Heart J; 1995 Aug; 16 Suppl H():19-24. PubMed ID: 8846801 [TBL] [Abstract][Full Text] [Related]
16. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Beckwith C; Munger MA Ann Pharmacother; 1993 Jun; 27(6):755-66. PubMed ID: 8329800 [TBL] [Abstract][Full Text] [Related]
17. Improvement of cardiac function by angiotensin converting enzyme inhibition. Sites of action. Dietz R; Waas W; Süsselbeck T; Willenbrock R; Osterziel KJ Circulation; 1993 May; 87(5 Suppl):IV108-16. PubMed ID: 8485825 [TBL] [Abstract][Full Text] [Related]
18. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Hornig B; Arakawa N; Drexler H Eur Heart J; 1998 Jul; 19 Suppl G():G48-53. PubMed ID: 9717056 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Dagenais GR; Pogue J; Fox K; Simoons ML; Yusuf S Lancet; 2006 Aug; 368(9535):581-8. PubMed ID: 16905022 [TBL] [Abstract][Full Text] [Related]
20. PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study--sub study of EUROPA: rationale and design. Bots ML; Remme WJ; Lüscher TF; Grobbee DE; Cardiovasc Drugs Ther; 2002 May; 16(3):227-36. PubMed ID: 12374901 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]